Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) and Forte Biosciences (NASDAQ:FBRX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.
Profitability
This table compares Pasithea Therapeutics and Forte Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pasithea Therapeutics | N/A | -151.82% | -135.28% |
| Forte Biosciences | N/A | -75.64% | -65.94% |
Earnings and Valuation
This table compares Pasithea Therapeutics and Forte Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pasithea Therapeutics | N/A | N/A | -$13.90 million | ($3.57) | -0.21 |
| Forte Biosciences | N/A | N/A | -$35.48 million | ($3.32) | -7.49 |
Forte Biosciences is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Pasithea Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 3.2, indicating that its stock price is 220% more volatile than the S&P 500.
Institutional and Insider Ownership
23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for Pasithea Therapeutics and Forte Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pasithea Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Forte Biosciences | 1 | 0 | 3 | 0 | 2.50 |
Pasithea Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 303.23%. Forte Biosciences has a consensus price target of $67.00, suggesting a potential upside of 169.51%. Given Pasithea Therapeutics’ higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Forte Biosciences.
Summary
Forte Biosciences beats Pasithea Therapeutics on 8 of the 11 factors compared between the two stocks.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
About Forte Biosciences
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
